Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

In Vitro Efficacy of Dalbavancin as an Anti-biofilm Long Acting Agent Loaded in Bone Cement

Mar Sánchez-Somolinos
,
Marta Díaz-Navarro
ORCID logo ,
Antonio Benjumea
,
José Matas
,
Javier Vaquero
,
Patricia Muñoz
ORCID logo ,
Pablo Sanz-Ruíz
ORCID logo ,
María Guembe
* ORCID logo
Version 1 : Received: 29 June 2023 / Approved: 30 June 2023 / Online: 30 June 2023 (14:38:03 CEST)

A peer-reviewed article of this Preprint also exists.

Sánchez-Somolinos, M.; Díaz-Navarro, M.; Benjumea, A.; Matas, J.; Vaquero, J.; Muñoz, P.; Sanz-Ruíz, P.; Guembe, M. In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement. Antibiotics 2023, 12, 1445. Sánchez-Somolinos, M.; Díaz-Navarro, M.; Benjumea, A.; Matas, J.; Vaquero, J.; Muñoz, P.; Sanz-Ruíz, P.; Guembe, M. In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement. Antibiotics 2023, 12, 1445.

Abstract

Based on previous studies of our group in which we demonstrated that dalbavancin loaded in bone cement had good elution capacity for the treatment of biofilm-related periprosthetic infections, we now assess the anti-biofilm activity of dalbavancin and compare it with that of vancomycin up to a 3-month period. We performed an in vitro model based on calculation of percentage reduction of log cfu/ml counts of sonicated steel discs contaminated with Staphylococci and further exposed to bone cement discs loaded with 2.5% or 5% vancomycin and dalbavancin at each study period (24 hours, 48 hours, 1 week, 2 weeks, 6 weeks, 3 months). In addition, we tested the anti-biofilm activity of eluted vancomycin and dalbavancin at each study period based on a 96-well plate model assessing percentage reduction of metabolic activity. Overall, dalbavancin showed a significant concentration decrease from 2 weeks of incubation and maintain its anti-biofilm activity up to 3 months, whereas, despite vancomycin showed a significant decrease at 1w and then it gradually increased, its anti-biofilm activity was significantly lower. Dalbavancin percentage reduction cfu/ml counts were higher than those of vancomycin, both at 2.5% and 5% concentrations. Reduction of log cfu/ml counts were higher for S. epidermidis than for S. aureus, being more notable for 5% dalbavancin at month 3. In addition, percentage reduction of metabolic activity also decreased at 3 months in 5% dalbavancin and 5% vancomycin, being more notable in the last.

Keywords

dalbavancin; bone cement; polymethylmethacrylate; elution; biofilm; vancomycin

Subject

Medicine and Pharmacology, Clinical Medicine

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.